Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 41K
5: R1 Cover HTML 47K
8: XML IDEA XML File -- Filing Summary XML 11K
6: XML XBRL Instance -- nmtr-20221101_htm XML 22K
7: EXCEL IDEA Workbook of Financial Reports XLSX 8K
3: EX-101.LAB XBRL Labels -- nmtr-20221101_lab XML 69K
4: EX-101.PRE XBRL Presentations -- nmtr-20221101_pre XML 34K
2: EX-101.SCH XBRL Schema -- nmtr-20221101 XSD 10K
9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
10: ZIP XBRL Zipped Folder -- 0001551986-22-000110-xbrl Zip 15K
(Address
of principal executive offices) (Zip Code)
(i919) i275-1933
(Registrant’s telephone number, include area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
iCommon
Stock $0.0001 Par Value
iNMTR
iThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth companyi☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01.
Other Events.
On November 1, 2022, 9 Meters Biopharma, Inc. (the “Company”) received written notification from Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company’s common stock had a closing price of $1.00 or greater for the ten consecutive trading days from October 18, 2022 to October 31, 2022 and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and that the matter is now closed.
As
previously reported, on February 8, 2022, Nasdaq notified the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to the Bid Price Rule. On August 9, 2022, the Company received formal notice that Nasdaq had granted the Company’s request for an extension through February 6, 2023 to evidence compliance with the Bid
Price Rule.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
